Board Meeting29 May 2026, 08:11 pm
Brooks Labs Approves Audited FY26 Financial Results
AI Summary
Brooks Laboratories Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The statutory auditors expressed an unmodified opinion on the results. The company's earlier plan to diversify its business segments has been shelved as the alteration to the Object Clause was not approved. Mr. Prashant Rathi has been appointed as CEO in addition to his role as CFO.
Key Highlights
- Audited financial results (standalone and consolidated) for FY26 approved with an unmodified audit opinion.
- Proposed alteration to the Object Clause of the Memorandum of Association not approved.
- Company to continue focusing on its core pharmaceutical operations.
- Mr. Prashant Rathi appointed as CEO in addition to his CFO role.
Price Impact
More from BROOKS